• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于测序的非酒精性脂肪性肝病患者肠道微生物群变化的系统评价和荟萃分析更新。

Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis.

机构信息

Department of Gastroenterology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.

出版信息

PLoS One. 2024 Mar 28;19(3):e0299946. doi: 10.1371/journal.pone.0299946. eCollection 2024.

DOI:10.1371/journal.pone.0299946
PMID:38547205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10977702/
Abstract

BACKGROUND

Alterations in the composition and abundance of the intestinal microbiota occur in non-alcoholic fatty liver disease (NAFLD). However, the results are inconsistent because of differences in the study design, subject area, and sequencing methodology. In this study, we compared the diversity and abundance of the intestinal microbiota of patients with NAFLD and healthy individuals through a systematic review and meta-analysis.

METHODS

Three databases (PubMed, EMBASE, and Cochrane Library) were searched from their inception to March 20, 2023. A meta-analysis was performed using Stata software to analyze variations in the richness and abundance of the intestinal microbiota in patients with NAFLD. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used for quality assessment.

RESULTS

A total of 28 articles were included. Shannon diversity was reduced in patients with NAFLD (SMD = -0.24 (95% CI -0.43-0.05, I2 = 71.7%). The relative abundance of Ruminococcus, Faecalibacterium, and Coprococcus all decreased, with total SMDs of -0.96 (95% CI -1.29 to -0.63, I2 = 4.8%), -1.13 (95% CI -2.07 to -0.19, I2 = 80.5%), and -1.66 (95% CI -3.04 to -0.28, I2 = 91.5%). Escherichia was increased in individuals with NAFLD (SMD = 1.78, 95% CI 0.12 to 3.45, I2 = 94.4%).

CONCLUSION

Increasing the species diversity and altering the abundance of specific gut microbiota, including Coprococcus, Faecalibacterium, Ruminococcus, and Escherichia, may be beneficial for improving NAFLD.

摘要

背景

非酒精性脂肪性肝病 (NAFLD) 患者的肠道微生物组成和丰度发生改变。然而,由于研究设计、研究对象和测序方法的不同,结果并不一致。在本研究中,我们通过系统评价和荟萃分析比较了 NAFLD 患者和健康个体肠道微生物的多样性和丰度。

方法

从数据库成立到 2023 年 3 月 20 日,我们在三个数据库(PubMed、EMBASE 和 Cochrane Library)中进行了检索。使用 Stata 软件对 NAFLD 患者肠道微生物的丰富度和丰度变化进行了荟萃分析。使用纽卡斯尔-渥太华质量评估量表(NOS)进行质量评估。

结果

共纳入 28 篇文章。NAFLD 患者的 Shannon 多样性降低(SMD=-0.24,95%CI-0.43-0.05,I2=71.7%)。瘤胃球菌、粪杆菌和真杆菌的相对丰度均降低,总 SMD 分别为-0.96(95%CI-1.29-0.63,I2=4.8%)、-1.13(95%CI-2.07-0.19,I2=80.5%)和-1.66(95%CI-3.04-0.28,I2=91.5%)。NAFLD 患者中大肠杆菌增加(SMD=1.78,95%CI0.12-3.45,I2=94.4%)。

结论

增加物种多样性和改变特定肠道微生物的丰度,包括真杆菌、粪杆菌、瘤胃球菌和大肠杆菌,可能有助于改善 NAFLD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/e8f7edf4939a/pone.0299946.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/f40be665bc44/pone.0299946.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/a07249f811e9/pone.0299946.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/c7372de9572c/pone.0299946.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/ca88b8bfeba3/pone.0299946.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/7a4fd4d74829/pone.0299946.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/e8f7edf4939a/pone.0299946.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/f40be665bc44/pone.0299946.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/a07249f811e9/pone.0299946.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/c7372de9572c/pone.0299946.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/ca88b8bfeba3/pone.0299946.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/7a4fd4d74829/pone.0299946.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c29e/10977702/e8f7edf4939a/pone.0299946.g006.jpg

相似文献

1
Changes in the intestinal microbiota of individuals with non-alcoholic fatty liver disease based on sequencing: An updated systematic review and meta-analysis.基于测序的非酒精性脂肪性肝病患者肠道微生物群变化的系统评价和荟萃分析更新。
PLoS One. 2024 Mar 28;19(3):e0299946. doi: 10.1371/journal.pone.0299946. eCollection 2024.
2
Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis.非酒精性脂肪性肝病患者肠道微生物群的组成改变:一项系统评价和Meta分析。
Lipids Health Dis. 2021 Feb 26;20(1):22. doi: 10.1186/s12944-021-01440-w.
3
Composition of gut microbiota and non-alcoholic fatty liver disease: A systematic review and meta-analysis.肠道微生物群组成与非酒精性脂肪性肝病:系统评价和荟萃分析。
Obes Rev. 2024 Jan;25(1):e13646. doi: 10.1111/obr.13646. Epub 2023 Oct 9.
4
The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.非酒精性肝病患者小肠细菌过度生长的患病率:NAFLD、NASH、纤维化、肝硬化-系统评价、荟萃分析和荟萃回归。
Nutrients. 2022 Dec 9;14(24):5261. doi: 10.3390/nu14245261.
5
Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?通过肠道微生物组表型非酒精性脂肪性肝病:准备好进入黄金时代了吗?
J Gastroenterol Hepatol. 2020 Nov;35(11):1969-1977. doi: 10.1111/jgh.15071. Epub 2020 Apr 30.
6
Gut microbiota alterations in colorectal adenoma-carcinoma sequence based on 16S rRNA gene sequencing: A systematic review and meta-analysis.基于 16S rRNA 基因测序的结直肠腺瘤-癌序列中肠道微生物组的改变:系统评价和荟萃分析。
Microb Pathog. 2024 Oct;195:106889. doi: 10.1016/j.micpath.2024.106889. Epub 2024 Aug 26.
7
Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.基于宏基因组学的非酒精性脂肪性肝病患者结肠黏膜活检样本肠道微生物菌群分布分析
Gene. 2022 Jul 30;833:146587. doi: 10.1016/j.gene.2022.146587. Epub 2022 May 19.
8
Role of intestinal flora in the development of nonalcoholic fatty liver disease in children.肠道菌群在儿童非酒精性脂肪性肝病发病机制中的作用。
Microbiol Spectr. 2024 Feb 6;12(2):e0100623. doi: 10.1128/spectrum.01006-23. Epub 2024 Jan 8.
9
The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial.健脾疏肝方通过调节肠道菌群治疗非酒精性脂肪性肝病的临床试验。
Front Endocrinol (Lausanne). 2023 Jan 19;13:1107071. doi: 10.3389/fendo.2022.1107071. eCollection 2022.
10
Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.了解肠道微生物组和微生物代谢物在非酒精性脂肪性肝病中的作用:当前的证据和观点。
Biomolecules. 2021 Dec 31;12(1):56. doi: 10.3390/biom12010056.

引用本文的文献

1
Association between the dietary index for gut microbiota and all-cause/cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease.肠道微生物群饮食指数与代谢功能障碍相关脂肪性肝病患者全因/心血管死亡率之间的关联
Diabetol Metab Syndr. 2025 Jul 11;17(1):263. doi: 10.1186/s13098-025-01846-x.
2
Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation.非酒精性脂肪性肝病中肠道-肝脏相关转录因子的调控:从跨器官相互作用到治疗创新
Biomedicines. 2025 Jun 10;13(6):1422. doi: 10.3390/biomedicines13061422.
3
Gut microbiota in liver diseases: initiation, development and therapy.

本文引用的文献

1
From complement to complosome in non-alcoholic fatty liver disease: When location matters.从非酒精性脂肪性肝病的补体到 complosome:当位置重要时。
Liver Int. 2024 Feb;44(2):316-329. doi: 10.1111/liv.15796. Epub 2023 Nov 27.
2
Faecalibacterium: a bacterial genus with promising human health applications.粪杆菌属:具有广阔人类健康应用前景的细菌属。
FEMS Microbiol Rev. 2023 Jul 5;47(4). doi: 10.1093/femsre/fuad039.
3
A metagenomic study identifies a Prevotella copri enriched microbial profile associated with non-alcoholic steatohepatitis in subjects with obesity.
肝脏疾病中的肠道微生物群:起始、发展与治疗
Front Med (Lausanne). 2025 Jun 4;12:1615839. doi: 10.3389/fmed.2025.1615839. eCollection 2025.
4
Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver.代谢功能障碍相关脂肪性肝病中营养、微生物群失调和免疫失调背景下的上皮屏障假说
Front Immunol. 2025 May 14;16:1575770. doi: 10.3389/fimmu.2025.1575770. eCollection 2025.
5
Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations.代谢功能障碍相关脂肪性肝病与肠道微生物群:致病机制洞察与治疗创新
J Clin Invest. 2025 Apr 1;135(7):e186423. doi: 10.1172/JCI186423.
6
Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).饮食对肠道微生物群的影响及其在代谢功能障碍相关脂肪性肝病(MASLD)中的作用
Nutrients. 2024 Dec 31;17(1):143. doi: 10.3390/nu17010143.
7
Emerging mechanisms of organ crosstalk: The role of oxylipins.器官串扰的新机制:氧化脂质的作用。
Nutr Bull. 2025 Mar;50(1):12-29. doi: 10.1111/nbu.12726. Epub 2024 Dec 10.
8
Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.以微生物群为中心的代谢功能障碍相关脂肪性肝病治疗方法
Clin Mol Hepatol. 2025 Feb;31(Suppl):S94-S111. doi: 10.3350/cmh.2024.0811. Epub 2024 Nov 28.
9
Modulatory effects of traditional Chinese medicines on gut microbiota and the microbiota-gut-x axis.中药对肠道微生物群及微生物-肠-肝轴的调节作用
Front Pharmacol. 2024 Oct 9;15:1442854. doi: 10.3389/fphar.2024.1442854. eCollection 2024.
10
Soybean oil-based HFD induces gut dysbiosis that leads to steatosis, hepatic inflammation and insulin resistance in mice.基于大豆油的高脂饮食会诱发肠道菌群失调,进而导致小鼠出现脂肪变性、肝脏炎症和胰岛素抵抗。
Front Microbiol. 2024 Aug 6;15:1407258. doi: 10.3389/fmicb.2024.1407258. eCollection 2024.
一项宏基因组学研究鉴定出与肥胖人群非酒精性脂肪性肝炎相关的富含普雷沃氏菌属的微生物特征。
J Gastroenterol Hepatol. 2023 May;38(5):791-799. doi: 10.1111/jgh.16147. Epub 2023 Mar 2.
4
, a Potent Probiotic, Alleviates Colitis via Acetate-Mediated IgA Response and Microbiota Restoration.一种强效益生菌通过乙酸介导的IgA反应和微生物群恢复来缓解结肠炎。
J Agric Food Chem. 2023 Feb 14. doi: 10.1021/acs.jafc.2c06697.
5
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)的全球流行病学:系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
6
The relationship of Megamonas species with nonalcoholic fatty liver disease in children and adolescents revealed by metagenomics of gut microbiota.宏基因组学揭示肠道微生物群与儿童和青少年非酒精性脂肪性肝病的 Megamonas 种的关系。
Sci Rep. 2022 Dec 20;12(1):22001. doi: 10.1038/s41598-022-25140-2.
7
Constitution of mucosa-associated microbiota in the lower digestive tract does not change in early stage of non-alcoholic fatty liver disease with fecal dysbiosis.在非酒精性脂肪性肝病早期且伴有粪便微生物群失调的情况下,下消化道黏膜相关微生物群的组成不会发生变化。
JGH Open. 2022 Aug 29;6(10):677-684. doi: 10.1002/jgh3.12803. eCollection 2022 Oct.
8
Integrative analysis of gut microbiota and fecal metabolites in metabolic associated fatty liver disease patients.代谢相关脂肪性肝病患者肠道微生物群与粪便代谢物的综合分析
Front Microbiol. 2022 Aug 22;13:969757. doi: 10.3389/fmicb.2022.969757. eCollection 2022.
9
Gut Microbiota-A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review.肠道微生物群——非酒精性脂肪性肝病患者的未来治疗靶点:系统评价。
Int J Mol Sci. 2022 Jul 27;23(15):8307. doi: 10.3390/ijms23158307.
10
Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus.代谢相关性脂肪性肝病和 2 型糖尿病患者的微生物组和代谢产物分析特征。
BMC Microbiol. 2022 Apr 15;22(1):105. doi: 10.1186/s12866-022-02526-w.